TOPAZ Trial Results on Muscle Therapy Likely by June, Scholar Rock Says

TOPAZ Trial Results on Muscle Therapy Likely by June, Scholar Rock Says

283159

TOPAZ Trial Results on Muscle Therapy Likely by June, Scholar Rock Says

Efficacy and safety results from the TOPAZ Phase 2 trial evaluating apitegromab, a  muscle-directed therapy for spinal muscular atrophy (SMA) being developed by Scholar Rock, are expected by June, the company announced. “2020 was a transformative year for Scholar Rock with … positive interim data from the TOPAZ trial providing initial proof-of-concept of apitegromab’s potential in SMA,” Tony Kingsley, president and CEO of Scholar Rock, said in a press release. “In 2021, we will further elucidate…

You must be logged in to read/download the full post.